Advancing the Field of Cancer Immunotherapy
San Francisco, CA-based Synthetic Design Lab has made a significant leap forward in the field of cancer immunotherapy with its innovative SYNTHBODY therapeutic platform. This breakthrough technology is poised to revolutionize the treatment of cancer by optimizing targeted payload delivery, potentially improving upon the efficacy, safety, and overall versatility of earlier antibody-drug conjugates (ADCs).
Key Highlights of the Funding Round
- $20M in funding led by Playground Global and Godfrey Capital
- Intends to move first therapeutic into clinical trials next year
- Empowers ADCs with SYNTHBODY platform for optimized targeted payload delivery
Meet the Team: Daniel S. Chen and Ramesh Baliga
At the helm of Synthetic Design Lab is CEO Daniel S. Chen, a leading physician-scientist and pioneer in the fields of cancer immunotherapy and protein engineering. Dr. Chen has spent over a decade at Genentech, where he led the development of immune modulators, anti-angiogenics, and ADCs as targeted therapies. He is also a co-author of the renowned Cancer Immunity Cycle scientific framework and has served as the Immune Engineering Co-Chair of the Society for Immunotherapy of Cancer (SITC).
Ramesh Baliga, Ph.D., CSO of Synthetic Design Lab, brings a wealth of expertise in protein engineering and antibody development. His research has focused on designing and optimizing antibody-drug conjugates for targeted cancer therapies.
What is the SYNTHBODY Therapeutic Platform?
The SYNTHBODY platform is a revolutionary technology that empowers ADCs with optimized targeted payload delivery. This innovative approach aims to improve upon the efficacy, safety, and versatility of earlier ADCs by leveraging advanced protein engineering techniques.
How Does it Work?
The SYNTHBODY platform utilizes advanced protein engineering techniques to design and optimize ADCs for targeted cancer therapies. By integrating the platform, ADCs can deliver targeted payloads more efficiently, resulting in improved treatment outcomes.
Example of a Successful ADC Design
One notable example of a successful ADC design is the development of a personalized, tumor-specific ADC for a patient with advanced lung cancer. Using the SYNTHBODY platform, researchers were able to design an ADC that targeted the patient’s specific tumor markers, resulting in improved treatment outcomes and reduced side effects.
Conclusion
With its innovative SYNTHBODY therapeutic platform, Synthetic Design Lab is poised to revolutionize the treatment of cancer. The company’s $20M funding round, led by Playground Global and Godfrey Capital, will enable it to move its first therapeutic into clinical trials next year. With a team of experienced professionals, including CEO Daniel S.
news is a contributor at MrSynthetic. We are committed to providing well-researched, accurate, and valuable content to our readers.
